Eagle Pharmaceuticals (EGRX) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 03, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	EAGLE PHARMACEUTICALS, INC.
Entity Central Index Key	827,871
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding (in shares)		15,636,387

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 78,287	$ 79,083
Accounts receivable	26,526	26,267
Inventories	7,761	15,042
Prepaid expenses and other current assets	2,048	1,865
Total current assets	114,622	122,257
Property and equipment, net	2,869	2,205
Intangible assets, net	11,116	0
Other assets	94	143
Total assets	128,701	124,605
Current liabilities:
Accounts payable	10,295	3,857
Accrued expenses	19,561	24,405
Current portion of contingent consideration	1,012	0
Deferred revenue	0	6,000
Total current liabilities	30,868	34,262
Contingent consideration	$ 5,517	$ 0
Commitments and contingencies
Stockholders' equity:
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of March 31, 2016 and December 31, 2015	$ 0	$ 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 15,636,387 issued and outstanding as of March 31, 2016 and December 31, 2015	15	15
Additional paid in capital	200,309	197,440
Accumulated deficit	(108,008)	(107,112)
Total stockholders' equity	92,316	90,343
Total liabilities and stockholders' equity	$ 128,701	$ 124,605

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	1,500,000	1,500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value per share (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	15,636,387	15,636,387
Common stock, shares outstanding (in shares)	15,636,387	15,636,387

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Product sales	$ 14,122	$ 3,056
Royalty income	9,469	3,253
License and other income	6,000	30,000
Total revenue	29,591	36,309
Operating expenses:
Cost of revenue	14,589	5,948
Research and development	6,676	6,285
Selling, general and administrative	10,973	3,986
Gain on sale of asset	(1,750)	0
Total operating expenses	30,488	16,219
Income (Loss) from operations	(897)	20,090
Interest income	21	7
Interest expense	(1)	(1)
Total other income	20	6
Income (Loss) before income tax provision	(877)	20,096
Income tax provision	(19)	(399)
Net Income (Loss)	$ (896)	$ 19,697
Earnings per share attributable to common stockholders:
Basic (in usd per share)	$ (0.06)	$ 1.38
Diluted (in usd per share)	$ (0.06)	$ 1.31
Weighted average number of common shares outstanding:
Basic (in shares)	15,636,387	14,247,019
Diluted (in shares)	15,636,387	15,041,011

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders' Equity - 3 months ended Mar. 31, 2016 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2015		15,637
Beginning balance at Dec. 31, 2015	$ 90,343	$ 15	$ 197,440	$ (107,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,869		2,869
Net income	(896)			(896)
Ending balance (in shares) at Mar. 31, 2016		15,637
Ending balance at Mar. 31, 2016	$ 92,316	$ 15	$ 200,309	$ (108,008)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (896)	$ 19,697
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation expense	140	12
Amortization of intangible assets	104	0
Stock-based compensation	2,869	384
Change in fair value of contingent consideration	159	0
Gain on sale of diclofenac-misoprostol	(1,750)	0
Loss on disposal of fixed assets	0	273
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(259)	1,448
Decrease (increase) in inventories	7,281	(776)
(Increase) decrease in prepaid expenses and other current assets	(183)	300
Decrease in other assets	49	0
Increase in accounts payable	6,438	1,884
(Decrease) increase in deferred revenue	(6,000)	65
(Decrease) increase in accrued expenses and other liabilities	(4,844)	2,549
Net cash provided by operating activities	3,108	25,836
Cash flows from investing activities:
Purchase of property and equipment	(804)	(43)
Purchase of short term investments	(62,000)	(15,998)
Cash used for acquisition	(4,850)	0
Proceeds from sale of diclofenac/misoprostol	1,750	0
Maturities of short term investments	62,000	0
Net cash used in investing activities	(3,904)	(16,041)
Cash flows from financing activities:
Proceeds from common stock option exercise	0	564
Proceeds from issuance of common stock from follow-on public offering, net of issuance costs	0	54,696
Net cash provided by financing activities	0	55,260
Net (decrease) increase in cash	(796)	65,055
Cash and cash equivalents at beginning of period	79,083	34,869
Cash and cash equivalents at end of period	78,287	99,924
Cash paid during the period for:
Interest	1	1
Corporate taxes	0	0
Franchise taxes	107	53
Non-cash financing activities
Accrued follow-on public offering costs	0	365
Contingent consideration on business acquisition	$ 6,370	$ 0

Interim Condensed Financial Sta

Interim Condensed Financial Statements	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Condensed Financial Statements	Interim Condensed Financial Statements The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results for the year ending December 31, 2016 or any period thereafter. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on February 29, 2016.

Organization and Business Activ

Organization and Business Activities	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Activities	Organization and Business Activities Eagle Pharmaceuticals, Inc. (the "Company", or "Eagle") is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the U.S. Food and Drug Administration's ("FDA's") 505(b)(2) NDA regulatory pathway. The Company's business model is to develop proprietary innovations to FDA-approved, injectable drugs, referred to as branded reference drugs, that offer favorable attributes to patients and healthcare providers. The Company has five products currently being sold in the United States under various license agreements in place with commercial partners, including a ready-to-use formulation of EP-1101 (argatroban) ("EP-1101"), Ryanodex ® (dantrolene sodium) ("Ryanodex"), diclofenac-misoprostol, docetaxel injection non-alcohol formulation ("Non-Alcohol Docetaxel Injection") and EP-3102 (rapidly infused bendamustine RTD) ("EP-3102 Bendeka"). The Company has a number of products currently under development and certain products may be subject to license agreements. On February 13, 2015, the Company submitted an NDA to the FDA for EP-3102 Bendeka, which was approved by the FDA on December 7, 2015. Also, on February 13, 2015, the Company entered into an Exclusive License Agreement (the “Cephalon License”) with Cephalon, Inc. ("Cephalon"), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. ("Teva"), for U.S. and Canadian rights to EP-3102 Bendeka for treatment of patients with CLL and patients with NHL. Pursuant to the terms of the Cephalon License, Cephalon will be responsible for all U.S. commercial activities for the product including promotion and distribution, and the Company is responsible for obtaining and maintaining all regulatory approvals and conducting post-approval clinical studies. Additionally, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , received a $15 million milestone payment in January 2016 related to the FDA approval of EP-3102 Bendeka in December 2015, and is currently eligible to receive up to $25 million in additional milestone payments. In addition, the Company is entitled to receive royalty payments of 20% of net sales of the product. In connection with the Cephalon License, the Company has entered into a supply agreement with Cephalon, pursuant to which the Company is responsible for supplying product to Cephalon for a specified period. On March 20, 2015, the Company completed an underwritten public offering (the "Follow-on Offering") of 1,518,317 shares of common stock, including the exercise by the underwriters of a 30 -day option to purchase an additional 198,041 shares of common stock. Of the shares sold, 1,388,517 shares were issued and offered by the Company and 129,800 shares were offered by certain selling stockholders. All of the shares were offered at a price to the public of $42.00 per share. The net proceeds to Eagle from this offering, after deducting underwriting discounts and commissions and other offering expenses payable by Eagle, were approximately $54,331 . Eagle did not receive any proceeds from the shares sold by the selling stockholders. The securities described above were offered pursuant to a shelf registration statement declared effective by the SEC on March 13, 2015. On October 13, 2015, the Company entered into an exclusive U.S. licensing agreement (the "Teikoku Agreement") with Teikoku Pharma USA, Inc. ("Teikoku") to market, sell and distribute Non-Alcohol Docetaxel Injection, an investigational product intended for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. The NDA for Non-Alcohol Docetaxel Injection for these indications was approved by the FDA on December 22, 2015. Under the terms of the agreement, the Company paid an upfront cash payment of $250 upon execution of the agreement which was expensed in 2015 and is included in research and development expense and an additional payment of $4,850 upon FDA approval and NDA transfer to Eagle, which occurred in January 2016. In addition, the Company will pay 25% royalties on gross profits. The Company accounted for the transaction as a business combination in 2016 and is in the process of finalizing the valuation of intangible assets and fair value of the contingent purchase price. As a result, the preliminary measurements of intangible assets are subject to change. The results of operations related to Non-Alcohol Docetaxel Injection have been included in the consolidated statements of income from the date of acquisition. On November 4, 2015, the Company entered into a co-promotion agreement with Spectrum Pharmaceuticals, Inc. ("Spectrum") under which Spectrum's 32 -person Corporate Accounts Sales Team will dedicate 80% of its time to selling and marketing up to six of the Company's products over a period of at least 18 months (the "Spectrum Agreement"). The Company will pay Spectrum a base fee of $12.8 million over 18 months, and additional payments of up to $9 million if specified targets for annual net sales of our products are met during the initial term of the Spectrum Agreement, for a potential total payment of up to $21.8 million during the initial term. The Company may extend the initial term of this agreement by six months to December 31, 2017 at its sole election. Any extensions after December 31, 2017 require mutual consent and will be for six months per extension. In addition to the services provided through the Spectrum Agreement and in line with our long-term strategy to build an internal commercial team, the Company hired approximately 12 direct sales representatives that will be a part of the Company's independent commercial organization. These representatives will be managed under the Spectrum sales team infrastructure for the duration of the Spectrum Agreement. On January 11, 2016, the Company entered into an agreement with Albany Molecular Research, Inc. ("AMRI") to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the United States. Under the terms of the agreement, AMRI will develop and initially provide cGMP manufacturing and analytical support for the registration of the new product candidates. The costs of development are to be shared, with 37.5% paid by the Company and 62.5% paid by AMRI. The Company will be responsible for advancing the product candidates through clinical trials and regulatory submissions. On March 18, 2016, the Company received a Complete Response Letter from the FDA for EP-6101 Kangio TM ready-to-use ("RTU") bivalirudin ("EP-6101 Kangio") in which the FDA stated it cannot approve the application in its present form and requested additional information from the Company. On March 28, 2016 the FDA denied the Company's request for seven years of orphan drug exclusivity in the U.S., for EP-3102 Bendeka. On March 29, 2016, the Company entered into an asset purchase agreement (the "Diclofenac Asset Purchase Agreement") pursuant to which the Company sold certain intellectual property related to diclofenac-misoprostol in the United States. In consideration of the assets and rights sold under the Diclofenac Asset Purchase Agreement, the Company received a one-time payment at closing of $1.75 million which was recognized a gain in the first quarter of 2016. In consideration of the rights granted under the agreement, the purchaser will pay the Company a 25% royalty on net profits of diclofenac-misoprostol in the territory for five years from the date of sale. The Company may continue to market diclofenac-misoprostol until such time that the purchaser is able to launch the product.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Accounting Guidance Not Yet Adopted In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective for us on January 1, 2018, however early adoption is permitted any time after the original effective date, which for us is January 1, 2017. We have not yet selected a transition method and are currently evaluating the impact of ASU 2014-09 on our financial statements. In November 2015, the FASB issued ASU 2015-17, which revises the guidance in ASC 740, Income Taxes, to simplify the presentation of deferred income taxes and require that deferred tax liabilities and assets be classified as non-current in the statement of financial position. The guidance is to be applied either prospectively or retrospectively, and is effective for reporting periods (interim and annual) beginning after December 15, 2016 for public companies. Early adoption is permitted. The implementation of this ASU is not expected to have a material impact on our financial position or results of operations. In January 2016, the FASB issued ASU 2016-01, which revises the guidance in ASC 825-10, Recognition and Measurement of Financial Assets and Financial Liabilities, and provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The guidance is effective for reporting periods (interim and annual) beginning after December 15, 2017, for public companies. We are currently assessing the potential impact of this ASU on our financial position and results of operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. For private companies, the amendments are effective for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on our financial position and results of operations. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations The effective date and transition of these amendments is the same as the effective date and transition of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Public entities should apply the amendments in ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). The Company is currently assessing the impact that this standard will have on our financial position and results of operations. The Company is currently evaluating the impact of its pending adoption of the new standard on its financial statements. Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company, at times, maintains balances with financial institutions in excess of the FDIC limit. Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents, accounts receivable, and accounts payable. The carrying values of these financial instruments approximate their fair values due to their short term maturities. Short Term Investments Investments consisted of U.S. Treasury securities that have an original maturity of greater than three months and typically less than 180 days. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Fair Value Measurements U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of interest-bearing cash, cash equivalents, short term investments, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 at March 31, 2016 and December 31, 2015 . The fair value of the contingent consideration/accrued royalty is classified as Level 3 at March 31, 2016 . The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis. Intangible Assets The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s revised useful life is changed, the Company will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life. Valuation of Acquisition-Related Contingent Consideration Contingent consideration related to a business combination is recorded at the acquisition date at the estimated fair value of the contingent payments. The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. The fair value of the acquisition-related contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in the consolidated statements of operations. Concentration of Major Customers and Vendors The Company is dependent on commercial partners to market and sell EP-1101 and EP-3102 Bendeka. The Company relies on its partner Teva to market EP-3102 Bendeka. The Company's customers for EP-1101 are its commercial and licensing partners, therefore, the Company's future revenues are highly dependent on these collaboration and distribution arrangements. The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows: Three Months Ended 2016 2015 Net revenues The Medicines Company 6 % 9 % Sandoz, Inc. 2 % 3 % Cephalon, Inc. (Teva) - See Revenue Recognition 61 % 83 % Par Pharmaceuticals Companies, Inc. - See Note 11 20 % — % Other 11 % 5 % 100 % 100 % March 31, December 31, 2016 2015 Accounts receivable The Medicines Company 32 % 35 % Sandoz, Inc. 1 % — % Cephalon, Inc. (Teva) - See Revenue Recognition 57 % 57 % Other 10 % 8 % 100 % 100 % Currently, for EP 1101 and EP-3102 Bendeka, the Company uses one vendor as its sole source supplier. Because of the unique equipment and process for manufacturing these products, transferring manufacturing activities to an alternate supplier would be a time consuming and costly endeavor, and there are only a limited number of manufacturers that are capable of performing this function for the Company. Inventory Inventories, which consist of finished products, are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers. Property and Equipment Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term. Impairment of Long-Lived Assets Long-lived assets and certain identifiable finite-lived intangible assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability of long-lived assets is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. Measurement of an impairment loss for long-lived assets and certain identifiable intangible assets that management expects to hold and use is based on the fair value of the asset. When an impairment loss is recognized, the carrying amount of the asset is reduced to its estimated fair value. There were no impairment charges recognized in three months ended March 31, 2016 and 2015 . Research and Development Expense Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or services performed. Advertising and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $2,404 and $959 for the three months ended March 31, 2016 and 2015 , respectively. Accounting for Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes . Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. During the three months ended March 31, 2016 and 2015, the Company recorded an income tax provision of $19 and $399 , respectively based upon its estimated federal AMT and state tax liability. Revenue Recognition Product revenue — The Company recognizes net revenue from EP-1101 and EP-3102 Bendeka supplied to its commercial partners and Non-Alcohol Docetaxel Injection, Ryanodex and diclofenac-misoprostol (see Note 11 "Asset Sales"), supplied to the end user, when the following four basic revenue recognition criteria under the related accounting guidance are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with cGMP. The Company's commercial partners can return the products within contracted specified timeframes if the products do not meet the applicable inspection tests. The Company estimates its return reserves based on its experience with historical return rates. Historically, product returns have not been material. The Company has a no return policy for Ryanodex. Revenues from product sales to end users are recorded net of provisions for estimated chargebacks, rebates, returns (if applicable), prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Eagle, the revenue is deferred to a future period when more information is available to evaluate the impact. Royalties — The Company recognizes revenue from royalties based on its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial. License revenue — The Company analyzes each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. When a sale combines multiple elements upon performance of multiple services, the Company allocates revenue for transactions that include multiple elements to each unit of accounting based on its relative selling price, and recognizes revenue for each unit of accounting when the revenue recognition criteria have been met. The Company follows the selling price hierarchy as outlined in the guidance Revenue Recognition (ASC Topic 605) - Multiple-Deliverable Revenue Arrangements . The guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence (“VSOE”), (ii) third-party evidence (“TPE”) if available and when VSOE is not available, and (iii) best estimate of the selling price (“BESP”) if neither VSOE nor TPE is available. The Company uses BESP to determine the standalone selling price for such deliverables. The Company has an established process for developing BESP, which incorporates pricing practices, historical selling prices, the effect of market conditions as well as entity-specific factors. Estimated selling price is monitored and evaluated on a regular basis to ensure that changes in circumstances are accounted for in a timely manner. The Company recognizes milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract. As described above, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , received a milestone payment of $15 million and is eligible to receive up to $25 million in additional milestone payments. The $30 million upfront payment was allocated between the license issued to Cephalon and obtaining and maintaining regulatory approvals and conducting post-approval clinical studies using the Company’s best estimate of selling price for each deliverable. The full $30 million was recognized as income in February 2015, as the Company substantially completed its requirements for obtaining regulatory approval, which consisted of filing a New Drug Application, or NDA, on February 13, 2015, and the remaining obligations were estimated to require minimal effort. On December 7, 2015, the FDA approved EP-3102 Bendeka (50 mL bendamustine hydrochloride) marking the achievement of a milestone which entitled the Company to a $15 million payment which was received in January 2016. The remaining milestones, if achieved, will be recognized in the period earned. In addition, the Company is entitled to royalty payments equal to 20% of net sales of the product. In connection with the Cephalon License, the Company agreed to enter into a supply agreement with Cephalon, pursuant to which the Company will be responsible for supplying product to Cephalon for a specified period. Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as well as the research and development performed by outside contractors or consultants. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors. The Company uses a Black-Scholes valuation model as the most appropriate valuation method for pricing these options. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees . Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock. The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions: Three Months Ended 2016 2015 Risk-free interest rate 1.29% - 1.90% 1.63% - 1.92% Volatility 31.31% 30.38% Expected term (in years) 5.50 - 7.00 years 5.50 - 7.00 years Expected dividend yield 0.0% 0.0% The risk-free rate assumption was based on U.S. Treasury instruments whose term was consistent with the expected term of the stock options. The expected stock price volatility was determined by examining the historical volatilities for industry peers as the Company did not have sufficient trading history for its common stock. Industry peers consist of those companies in the pharmaceutical industry similar in size, stage of life-cycle and financial leverage. The expected term of stock options represents the average of the vesting period and the contractual life of the option for employees and the life of the option for consultants. The expected dividend assumption is based on the Company's history and expectation of future dividend payouts. Changes in the estimated forfeiture rates are reflected prospectively. Earnings (Loss) Per Share Basic earnings (loss) per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings (loss) per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. The anti-dilutive common shares equivalents outstanding at the three months ended March 31, 2016 and 2015 were as follows: Three Months Ended 2016 2015 Options 2,510,702 118,619 Total 2,510,702 118,619 The following table sets forth the computation for basic and diluted net income (loss) per share for the three months ended March 31, 2016 and 2015 : Three Months Ended 2016 2015 Numerator Numerator for basic earnings per share-net (loss) income $ (896 ) $ 19,697 Numerator for diluted earnings per share-net (loss) income $ (896 ) $ 19,697 Denominator Basic weighted average common shares outstanding 15,636,387 14,247,019 Dilutive effect of stock options — 793,992 Diluted weighted average common shares outstanding 15,636,387 15,041,011 Basic net (loss) income per share Basic net (loss) income per share $ (0.06 ) $ 1.38 Diluted net (loss) income per share Diluted net (loss) income per share $ (0.06 ) $ 1.31

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of Docetaxel-Injection, Non-Alcohol Formula On October 13, 2015, the Company entered into the Teikoku Agreement with Teikoku to market, sell and distribute Non-Alcohol Docetaxel Injection, an investigational product intended for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. The NDA for Non-Alcohol Docetaxel Injection for these indications was approved by the FDA on December 22, 2015. Under the terms of the agreement, the Company paid an upfront cash payment of $250 upon execution of the agreement which was expensed in 2015 and was included in research and development expense and an additional payment of $4,850 upon FDA approval and NDA transfer to the Company which occurred on January 12, 2016. In addition, the Company will pay 25% royalties on gross profits. The Company accounted for the transaction as a purchase of a business in 2016, in accordance with FASB Accounting Standard Codification 805 Business Combinations. The Company is in the process of finalizing the valuation of intangible assets and fair value of the contingent purchase price. As a result, the preliminary measurements of fair value of the contingent consideration payments on the acquisition date was $6,370 as of the acquisition date and the total amount capitalized as an intangible asset was $11,220 . The Company estimated the fair value of this contingent consideration based on forecasted revenues reflecting the Company's own assumptions concerning future revenue from such product. Acquisition contingent consideration is measured at fair value on a recurring basis using unobservable inputs; which accordingly represents a Level 3 measurement within the fair value hierarchy. The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through March 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance January 12, 2016 $ 6,370 Changes in fair value 159 Closing Balance March 31, 2016 $ 6,529 The following table displays the balance sheet classification of the contingent consideration liability account as of March 31, 2016 and the acquisition date, January 12, 2016: March 31, January 12, 2016 2016 Accrued royalty payable $ 1,012 $ 1,012 Long term royalty payable 5,517 5,358 Total acquisition related contingent consideration $ 6,529 $ 6,370 The results of operations related to Docetaxel Non-Alcohol Injection have been included in the consolidated statements of income from the date of acquisition. Pro forma results of operations have not been presented because the effect of Docetaxel Non-Alcohol Injection was not material. The Company recorded product sales of Non-Alcohol Docetaxel Injection of $868 and a net loss of $867 in the three months ended March 31, 2016 . The Company did not incur any significant acquisition related costs in connection with the Non-Alcohol Docetaxel injection acquisition. The fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Any change in fair value of the contingent consideration subsequent to the acquisition date is recognized in operating income within the condensed statement of operations.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: March 31, December 31, 2016 2015 Raw material $ 5,208 $ 8,687 Work in process — 6,044 Finished products 2,553 311 $ 7,761 $ 15,042

Balance Sheet Accounts

Balance Sheet Accounts	3 Months Ended
	Mar. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Prepaid and Other Current Assets Prepaid and other current assets consist of the following: March 31, December 31, 2016 2015 Prepaid expenses and other current assets Prepaid product costs $ 134 $ 85 Prepaid FDA user fee 373 551 Prepaid insurance 651 218 Prepaid research and development 194 283 Prepaid income taxes 489 508 All other 207 220 Total Prepaid expenses and other current assets $ 2,048 $ 1,865 Accrued Expenses Accrued expenses consist of the following: March 31, December 31, 2016 2015 Accrued expenses Royalties due to The Medicines Company $ 7,166 $ 6,948 Royalties due to SciDose 1,474 1,637 Royalties due to Sandoz, Inc. 813 1,249 Accrued research & development 1,258 1,784 Accrued professional fees 817 792 Accrued salary and other compensation 1,149 2,242 Accrued product costs 5,918 9,232 Accrued other 428 — Deferred rent 538 521 Total Accrued expenses $ 19,561 $ 24,405 Deferred Revenue Deferred revenue consists of the following: March 31, December 31, 2016 2015 Deferred revenue Par Pharmaceuticals Companies, Inc. (See Note 11) $ — $ 5,500 Par Pharmaceuticals Companies, Inc./Tech Transfer — 500 Deferred Revenue from Asset Sales — 6,000 Total Deferred revenue $ — $ 6,000

Intangible Asset

Intangible Asset	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset	Intangible Asset The gross carrying amounts and net book value of our intangible asset are as follows: March 31, 2016 December 31, 2015 Useful Life (In Years) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Docetaxel product rights 18 $ 11,220 $ (104 ) $ 11,116 $ — $ — $ — Total 18 $ 11,220 $ (104 ) $ 11,116 $ — $ — $ — Amortization expense was $104 and $0 for three months ended March 31, 2016 and 2015 , respectively. Based on finite-lived intangible assets recorded as of March 31, 2016, and assuming the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows: Estimated Amortization Expense Year Ending December 31, 2016 (remainder) $ 468 2017 623 2018 623 2019 623 2020 623 All other 8,156 Total estimated amortization expense $ 11,116

Common Stock and Stock-Based Co

Common Stock and Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock and Stock-Based Compensation	Common Stock and Stock-Based Compensation In December 2007, the Company's board of directors approved the 2007 Incentive Compensation Plan (the "2007 Plan") enabling the Company to grant multiple stock based awards to employees, directors and consultants, the most common being stock options and restricted stock awards. In November 2013, the Company's board of directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2007 Plan was terminated upon the effectiveness of the 2014 Plan and all shares available for issuance under the 2007 Plan were made available under the 2014 Plan. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant date. Vesting is accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited. At the Company's annual meeting of stockholders held on August 4, 2015, the stockholders approved an amendment to the 2014 Plan to, among other things, increase the number of shares of common stock authorized for issuance thereunder by 500,000 shares. After accounting for such increase, the Company has reserved and made available 2,035,598 shares of common stock for issuance under the 2014 Plan. The Company recognized share-based compensation in its statements of operations for the three months ended March 31, 2016 and 2015 as follows: Three Months Ended 2016 2015 Selling, general and administrative $ 2,162 $ 200 Research and development 707 184 Total $ 2,869 $ 384

Commitments

Commitments	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments At March 31, 2016 , the Company has purchase obligations in the amount of $21,345 which represent the contractual commitments under Contract Manufacturing and Supply Agreements with suppliers. The obligation under the supply agreement is primarily for finished product, inventory, and research and development. The Company leases its office space under a lease agreement that expires on June 30, 2020 . Rental expense was $162 and $68 for the three months ended March 31, 2016 and 2015 , respectively. The future lease payments under the operating lease are $2,396 as of March 31, 2016 , payable monthly through June 30, 2020. Total 2016 2017 2018 2019 2020 Beyond Operating lease obligations $ 2,396 423 564 564 564 281 — Purchase obligations $ 21,345 21,345

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Claims and lawsuits may be filed against the Company from time to time. Although the results of pending claims are always uncertain, the Company believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from such actions. In September 2013, the Company filed an NDA under Section 505(b)(2) for EP-3101(bendamustine RTD) ("EP-3101"), the Company's bendamustine hydrochloride injection, in a ready-to-dilute concentrate solution, product ("bendamustine RTD") and notified Cephalon, the holder of Treanda ® , the referenced approved drug in our application, of the Company's 505(b)(2) filing and paragraph IV certification. Cephalon filed a patent infringement lawsuit against the Company in the United States District Court for the District of Delaware on October 21, 2013 to defer the approval of the bendamustine indication alleging that the Company's tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents, U.S. Patent No. 8,445,524 (the "First Cephalon Lawsuit"). In July 2014, the FDA had granted tentative approval and orphan drug designation to the Company’s NDA for patented bendamustine RTD for the treatment of NHL. In September 2014, Cephalon moved to dismiss with prejudice the First Cephalon Lawsuit. On August 12, 2014, Cephalon filed a second lawsuit in the District of Delaware alleging that bendamustine RTD infringes Cephalon’s newly-issued U.S. Patent No. 8,791,270 (the "Second Cephalon Lawsuit"). On February 13, 2015, the Company and Cephalon entered into the Cephalon Settlement Agreement pursuant to which the parties agreed to settle the Second Cephalon Lawsuit, under which the Company has agreed to enter into the Consent Judgment regarding the ‘270 patent. As part of the Cephalon Settlement Agreement, Cephalon has agreed to waive its orphan drug exclusivities for the treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma with EP-3102 Bendeka. In February 2016, The Medicines Company (“MDCO”) filed a complaint against the Company, SciDose LLC and TherDose Pharma Pvt. Ltd. (collectively the “Defendants”) relating to the Defendants’ work on a novel ready-to-use bivalirudin injection product (the “Bivalirudin Product”). The suit cites the May 7, 2008 License and Development Agreement (the “LDA”) between the Defendants and MDCO. In the lawsuit, MDCO alleges that the Company violated the terms of the LDA by, inter alia , developing the Bivalirudin Product, and that the Company's Bivalirudin Product infringes two patents that are jointly-owned by the Company and MDCO and violates an exclusive license that MDCO claims exists under the LDA. The Company disputes the allegations and believes it has meritorious defenses to all of MDCO’s allegations. On April 27, 2016, the Company filed an action in the U.S. District Court for the District of Columbia against the FDA and other federal defendants seeking an order requiring the FDA to grant us orphan drug exclusivity for EP-3102 Bendeka for the treatment of CLL and indolent B-cell NHL. The Company believes EP-3102 Bendeka is entitled to orphan drug exclusivity as a matter of law, and that the FDA’s decision violates federal law and is inconsistent with the holding of the U.S. District Court for the District of Columbia in Depomed Inc. v. U.S. Department of Health and Human Services. The FDA has not yet responded to the Company’s complaint.

Asset Sales

Asset Sales	3 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
Asset Sales	Asset Sales During fiscal year 2010 and 2011, the Company divested another non-core product and received proceeds of $6,500 , comprised of $5,500 as a signing milestone which was previously recorded in deferred revenues and $500 for the initiation of Tech Transfer of which $250 previously remained in deferred revenues and a second payment of $500 for the completion of the Tech Transfer of which $250 previously remained in deferred revenues. Under the terms of this agreement, the licensor must obtain all of the following milestones with regard to the filing of the product in order for the Company to earn the revenues. These milestones are a) the receipt of an approval letter from the FDA, b) acknowledgment from the FDA that no further clinical studies will be needed and c) an approval letter from the FDA. The Company, through various requests for information, was informed by the licensor in 2016 that it had voluntarily withdrawn the filing of the product application from the FDA in a prior year. Under the terms of the agreement, the milestones required to earn the $6,000 previously included in deferred revenue, were with regard to the filing. The voluntary withdrawal of the filing by the licensor relieved the Company of further obligation with regard to performance under the milestones. During the quarter ended March 31, 2016, the Company recognized the $6,000 as Other revenue. On March 29, 2016, the Company entered into the Diclofenac Asset Purchase Agreement pursuant to which the Company sold certain intellectual property related to diclofenac-misoprostol in the United States. In consideration of the assets and rights sold under the Diclofenac Asset Purchase Agreement, the Company received a one-time payment at closing of $1.75 million , which was recognized as a gain in the first quarter of 2016. In consideration of the rights granted under the Diclofenac Asset Purchase Agreement, the purchaser will pay the Company a 25% royalty on net profits of diclofenac-misoprostol in the territory for five years from the date of sale. The Company may continue to market diclofenac-misoprostol until such time that the purchaser is able to launch.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Accounting Guidance Not Yet Adopted	Accounting Guidance Not Yet Adopted In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective for us on January 1, 2018, however early adoption is permitted any time after the original effective date, which for us is January 1, 2017. We have not yet selected a transition method and are currently evaluating the impact of ASU 2014-09 on our financial statements. In November 2015, the FASB issued ASU 2015-17, which revises the guidance in ASC 740, Income Taxes, to simplify the presentation of deferred income taxes and require that deferred tax liabilities and assets be classified as non-current in the statement of financial position. The guidance is to be applied either prospectively or retrospectively, and is effective for reporting periods (interim and annual) beginning after December 15, 2016 for public companies. Early adoption is permitted. The implementation of this ASU is not expected to have a material impact on our financial position or results of operations. In January 2016, the FASB issued ASU 2016-01, which revises the guidance in ASC 825-10, Recognition and Measurement of Financial Assets and Financial Liabilities, and provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The guidance is effective for reporting periods (interim and annual) beginning after December 15, 2017, for public companies. We are currently assessing the potential impact of this ASU on our financial position and results of operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. For private companies, the amendments are effective for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on our financial position and results of operations. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments relate to when another party, along with the entity, is involved in providing a good or service to a customer. Topic 606 Revenue from Contracts with Customers requires an entity to determine whether the nature of its promise is to provide that good or service to the customer (i.e., the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is an agent). The amendments are intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations The effective date and transition of these amendments is the same as the effective date and transition of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Public entities should apply the amendments in ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). The Company is currently assessing the impact that this standard will have on our financial position and results of operations. The Company is currently evaluating the impact of its pending adoption of the new standard on its financial statements.
Reclassifications	Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company's financial instruments consist of cash and cash equivalents, accounts receivable, and accounts payable. The carrying values of these financial instruments approximate their fair values due to their short term maturities.
Short Term Investments	Short Term Investments Investments consisted of U.S. Treasury securities that have an original maturity of greater than three months and typically less than 180 days. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Fair Value Measurements	Fair Value Measurements U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of interest-bearing cash, cash equivalents, short term investments, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 at March 31, 2016 and December 31, 2015 . The fair value of the contingent consideration/accrued royalty is classified as Level 3 at March 31, 2016 . The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis.
Intangible Assets	Intangible Assets The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s revised useful life is changed, the Company will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life.
Valuation of Acquisition-Related Contingent Consideration	Valuation of Acquisition-Related Contingent Consideration Contingent consideration related to a business combination is recorded at the acquisition date at the estimated fair value of the contingent payments. The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. The fair value of the acquisition-related contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in the consolidated statements of operations.
Concentration of Major Customers and Vendors	Concentration of Major Customers and Vendors The Company is dependent on commercial partners to market and sell EP-1101 and EP-3102 Bendeka. The Company relies on its partner Teva to market EP-3102 Bendeka. The Company's customers for EP-1101 are its commercial and licensing partners, therefore, the Company's future revenues are highly dependent on these collaboration and distribution arrangements.
Inventory	Inventory Inventories, which consist of finished products, are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets and certain identifiable finite-lived intangible assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability of long-lived assets is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. Measurement of an impairment loss for long-lived assets and certain identifiable intangible assets that management expects to hold and use is based on the fair value of the asset. When an impairment loss is recognized, the carrying amount of the asset is reduced to its estimated fair value.
Research and Development Expense	Research and Development Expense Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or services performed.
Advertising and Marketing	Advertising and Marketing Advertising and marketing costs are expensed as incurred.
Accounting for Income Taxes	Accounting for Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes . Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.
Revenue Recognition	Revenue Recognition Product revenue — The Company recognizes net revenue from EP-1101 and EP-3102 Bendeka supplied to its commercial partners and Non-Alcohol Docetaxel Injection, Ryanodex and diclofenac-misoprostol (see Note 11 "Asset Sales"), supplied to the end user, when the following four basic revenue recognition criteria under the related accounting guidance are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with cGMP. The Company's commercial partners can return the products within contracted specified timeframes if the products do not meet the applicable inspection tests. The Company estimates its return reserves based on its experience with historical return rates. Historically, product returns have not been material. The Company has a no return policy for Ryanodex. Revenues from product sales to end users are recorded net of provisions for estimated chargebacks, rebates, returns (if applicable), prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Eagle, the revenue is deferred to a future period when more information is available to evaluate the impact. Royalties — The Company recognizes revenue from royalties based on its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial. License revenue — The Company analyzes each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. When a sale combines multiple elements upon performance of multiple services, the Company allocates revenue for transactions that include multiple elements to each unit of accounting based on its relative selling price, and recognizes revenue for each unit of accounting when the revenue recognition criteria have been met. The Company follows the selling price hierarchy as outlined in the guidance Revenue Recognition (ASC Topic 605) - Multiple-Deliverable Revenue Arrangements . The guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence (“VSOE”), (ii) third-party evidence (“TPE”) if available and when VSOE is not available, and (iii) best estimate of the selling price (“BESP”) if neither VSOE nor TPE is available. The Company uses BESP to determine the standalone selling price for such deliverables. The Company has an established process for developing BESP, which incorporates pricing practices, historical selling prices, the effect of market conditions as well as entity-specific factors. Estimated selling price is monitored and evaluated on a regular basis to ensure that changes in circumstances are accounted for in a timely manner. The Company recognizes milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract. As described above, under the terms of the Cephalon License, the Company received an upfront cash payment of $30 million , received a milestone payment of $15 million and is eligible to receive up to $25 million in additional milestone payments. The $30 million upfront payment was allocated between the license issued to Cephalon and obtaining and maintaining regulatory approvals and conducting post-approval clinical studies using the Company’s best estimate of selling price for each deliverable. The full $30 million was recognized as income in February 2015, as the Company substantially completed its requirements for obtaining regulatory approval, which consisted of filing a New Drug Application, or NDA, on February 13, 2015, and the remaining obligations were estimated to require minimal effort. On December 7, 2015, the FDA approved EP-3102 Bendeka (50 mL bendamustine hydrochloride) marking the achievement of a milestone which entitled the Company to a $15 million payment which was received in January 2016. The remaining milestones, if achieved, will be recognized in the period earned. In addition, the Company is entitled to royalty payments equal to 20% of net sales of the product. In connection with the Cephalon License, the Company agreed to enter into a supply agreement with Cephalon, pursuant to which the Company will be responsible for supplying product to Cephalon for a specified period. Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as well as the research and development performed by outside contractors or consultants. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors. The Company uses a Black-Scholes valuation model as the most appropriate valuation method for pricing these options. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees . Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock. The risk-free rate assumption was based on U.S. Treasury instruments whose term was consistent with the expected term of the stock options. The expected stock price volatility was determined by examining the historical volatilities for industry peers as the Company did not have sufficient trading history for its common stock. Industry peers consist of those companies in the pharmaceutical industry similar in size, stage of life-cycle and financial leverage. The expected term of stock options represents the average of the vesting period and the contractual life of the option for employees and the life of the option for consultants. The expected dividend assumption is based on the Company's history and expectation of future dividend payouts. Changes in the estimated forfeiture rates are reflected prospectively.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic earnings (loss) per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings (loss) per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Revenues and Accounts Receivables By Major Customers	The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows: Three Months Ended 2016 2015 Net revenues The Medicines Company 6 % 9 % Sandoz, Inc. 2 % 3 % Cephalon, Inc. (Teva) - See Revenue Recognition 61 % 83 % Par Pharmaceuticals Companies, Inc. - See Note 11 20 % — % Other 11 % 5 % 100 % 100 % March 31, December 31, 2016 2015 Accounts receivable The Medicines Company 32 % 35 % Sandoz, Inc. 1 % — % Cephalon, Inc. (Teva) - See Revenue Recognition 57 % 57 % Other 10 % 8 % 100 % 100 %
Fair Value of Stock Options	The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions: Three Months Ended 2016 2015 Risk-free interest rate 1.29% - 1.90% 1.63% - 1.92% Volatility 31.31% 30.38% Expected term (in years) 5.50 - 7.00 years 5.50 - 7.00 years Expected dividend yield 0.0% 0.0%
Schedule of Dilutive and Anti-Dilutive Common Shares Equivalents Outstanding	The anti-dilutive common shares equivalents outstanding at the three months ended March 31, 2016 and 2015 were as follows: Three Months Ended 2016 2015 Options 2,510,702 118,619 Total 2,510,702 118,619
Computation for Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the computation for basic and diluted net income (loss) per share for the three months ended March 31, 2016 and 2015 : Three Months Ended 2016 2015 Numerator Numerator for basic earnings per share-net (loss) income $ (896 ) $ 19,697 Numerator for diluted earnings per share-net (loss) income $ (896 ) $ 19,697 Denominator Basic weighted average common shares outstanding 15,636,387 14,247,019 Dilutive effect of stock options — 793,992 Diluted weighted average common shares outstanding 15,636,387 15,041,011 Basic net (loss) income per share Basic net (loss) income per share $ (0.06 ) $ 1.38 Diluted net (loss) income per share Diluted net (loss) income per share $ (0.06 ) $ 1.31

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Schedule of Contingent Consideration Liability	The following table displays the balance sheet classification of the contingent consideration liability account as of March 31, 2016 and the acquisition date, January 12, 2016: March 31, January 12, 2016 2016 Accrued royalty payable $ 1,012 $ 1,012 Long term royalty payable 5,517 5,358 Total acquisition related contingent consideration $ 6,529 $ 6,370 The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability since acquisition through March 31, 2016 which was recorded in selling, general and administrative expense in the condensed statements of operations: Opening Balance January 12, 2016 $ 6,370 Changes in fair value 159 Closing Balance March 31, 2016 $ 6,529

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following: March 31, December 31, 2016 2015 Raw material $ 5,208 $ 8,687 Work in process — 6,044 Finished products 2,553 311 $ 7,761 $ 15,042

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	3 Months Ended
	Mar. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following: March 31, December 31, 2016 2015 Prepaid expenses and other current assets Prepaid product costs $ 134 $ 85 Prepaid FDA user fee 373 551 Prepaid insurance 651 218 Prepaid research and development 194 283 Prepaid income taxes 489 508 All other 207 220 Total Prepaid expenses and other current assets $ 2,048 $ 1,865
Schedule of Accrued Expenses	Accrued expenses consist of the following: March 31, December 31, 2016 2015 Accrued expenses Royalties due to The Medicines Company $ 7,166 $ 6,948 Royalties due to SciDose 1,474 1,637 Royalties due to Sandoz, Inc. 813 1,249 Accrued research & development 1,258 1,784 Accrued professional fees 817 792 Accrued salary and other compensation 1,149 2,242 Accrued product costs 5,918 9,232 Accrued other 428 — Deferred rent 538 521 Total Accrued expenses $ 19,561 $ 24,405
Schedule of Deferred Revenue	Deferred revenue consists of the following: March 31, December 31, 2016 2015 Deferred revenue Par Pharmaceuticals Companies, Inc. (See Note 11) $ — $ 5,500 Par Pharmaceuticals Companies, Inc./Tech Transfer — 500 Deferred Revenue from Asset Sales — 6,000 Total Deferred revenue $ — $ 6,000

Intangible Asset (Tables)

Intangible Asset (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Asset	The gross carrying amounts and net book value of our intangible asset are as follows: March 31, 2016 December 31, 2015 Useful Life (In Years) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Docetaxel product rights 18 $ 11,220 $ (104 ) $ 11,116 $ — $ — $ — Total 18 $ 11,220 $ (104 ) $ 11,116 $ — $ — $ —
Schedule of Future Amortization Expense of Finite-Lived Intangible Assets	Based on finite-lived intangible assets recorded as of March 31, 2016, and assuming the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows: Estimated Amortization Expense Year Ending December 31, 2016 (remainder) $ 468 2017 623 2018 623 2019 623 2020 623 All other 8,156 Total estimated amortization expense $ 11,116

Common Stock and Stock-Based 24

Common Stock and Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Recognized in Statements of Operations	The Company recognized share-based compensation in its statements of operations for the three months ended March 31, 2016 and 2015 as follows: Three Months Ended 2016 2015 Selling, general and administrative $ 2,162 $ 200 Research and development 707 184 Total $ 2,869 $ 384

Commitments (Tables)

Commitments (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Obligations and Purchase Obligations	Total 2016 2017 2018 2019 2020 Beyond Operating lease obligations $ 2,396 423 564 564 564 281 — Purchase obligations $ 21,345 21,345

Organization and Business Act26

Organization and Business Activities (Details)	Jan. 12, 2016USD ($)	Jan. 11, 2016	Nov. 04, 2015USD ($)productperson	Oct. 13, 2015USD ($)	Mar. 20, 2015USD ($)$ / sharesshares	Feb. 13, 2015USD ($)	Jan. 31, 2016USD ($)	Mar. 31, 2016USD ($)productperson	Mar. 31, 2015USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of products | product								5
Payments to acquire business								$ 4,850,000	$ 0
Number of sales representatives hired | person								12
Proceeds from sale of diclofenac/misoprostol								$ 1,750,000	$ 0
Follow-on Offering
Subsidiary, Sale of Stock [Line Items]
Other offering expenses payable					$ 54,331,000
Common Stock | Follow-on Offering
Subsidiary, Sale of Stock [Line Items]
Shares issued | shares					1,518,317
Issuance of common stock, additional period underwriters may purchase					30 days
Issuance of common stock, number of shares underwriters may purchase during additional period | shares					198,041
Issuance of common stock, net of offering costs (in shares) | shares					1,388,517
Issuance of common stock, portion from stockholders (in shares) | shares					129,800
Share price (in usd per share) | $ / shares					$ 42
Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Upfront cash payment for license agreement						$ 30,000,000
Milestone payment received							$ 15,000,000
Maximum additional milestone payments (up to)								$ 25,000,000
Royalty revenue, percentage of net sales								20.00%
Diclofenac-misoprostol
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of diclofenac/misoprostol								$ 1,750,000
Royalty revenue, percentage of gross profits								25.00%
Royalty revenue term								5 years
AMRI | Jointly Develop and Manufacture Drug Products | Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Cost sharing percentage		62.50%
Spectrum | Spectrum Agreement | Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Number of products | product			6
Number of employees on the Corporate Accounts Sales Team | person			32
Percentage of time allocated			80.00%
Service period (at least)			18 months
Base fee			$ 12,800,000
Base fee, payment period			18 months
Maximum additional payment (up to)			$ 9,000,000
Maximum potential payment (up to)			$ 21,800,000
Extension term			6 months
AMRI | Jointly Develop and Manufacture Drug Products | Affiliated Entity
Subsidiary, Sale of Stock [Line Items]
Cost sharing percentage		37.50%
Bendeka
Subsidiary, Sale of Stock [Line Items]
Exclusive rights, term								7 years
Non-Alcohol Docetaxel Injection | Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Payments to acquire business	$ 4,850,000			$ 250,000
Royalties on Gross Profits | Non-Alcohol Docetaxel Injection | Docetaxel product rights
Subsidiary, Sale of Stock [Line Items]
Contingent consideration, percentage of gross profits	25.00%

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	Feb. 13, 2015	Jan. 31, 2016	Feb. 28, 2015	Mar. 31, 2016	Mar. 31, 2015
Revenue Recognition, Milestone Method [Line Items]
License and other income				$ 6,000,000	$ 30,000,000
Impairment of long-lived assets				0	0
Advertising and marketing costs				2,404,000	959,000
Income tax provision				$ 19,000	$ 399,000
Period after quarter commercial partners report net product sales				60 days
Cephalon, Inc.
Revenue Recognition, Milestone Method [Line Items]
Upfront cash payment for license agreement	$ 30,000,000
Milestone payment received		$ 15,000,000
Maximum additional milestone payments (up to)				$ 25,000,000
License and other income			$ 30,000,000
Royalty revenue, percentage of net sales				20.00%

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Net Revenues
Concentration Risk [Line Items]
Percentage of concentration	100.00%	100.00%
Net Revenues | The Medicines Company
Concentration Risk [Line Items]
Percentage of concentration	6.00%	9.00%
Net Revenues | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration	2.00%	3.00%
Net Revenues | Cephalon, Inc.
Concentration Risk [Line Items]
Percentage of concentration	61.00%	83.00%
Net Revenues | Par Pharmaceuticals Companies, Inc.
Concentration Risk [Line Items]
Percentage of concentration	20.00%	0.00%
Net Revenues | Other
Concentration Risk [Line Items]
Percentage of concentration	11.00%	5.00%
Accounts Receivable
Concentration Risk [Line Items]
Percentage of concentration	100.00%		100.00%
Accounts Receivable | The Medicines Company
Concentration Risk [Line Items]
Percentage of concentration	32.00%		35.00%
Accounts Receivable | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration	1.00%		0.00%
Accounts Receivable | Cephalon, Inc.
Concentration Risk [Line Items]
Percentage of concentration	57.00%		57.00%
Accounts Receivable | Other
Concentration Risk [Line Items]
Percentage of concentration	10.00%		8.00%

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Assumption of Stock Options Granted (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest minimum rate	1.29%	1.63%
Risk-free interest maximum rate	1.90%	1.92%
Volatility	31.31%	30.38%
Expected dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years 6 months	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	7 years	7 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding (in shares)	2,510,702	118,619
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding (in shares)	2,510,702	118,619

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies [Abstract]
Numerator for basic earnings per share-net (loss) income	$ (896)	$ 19,697
Numerator for diluted earnings per share-net (loss) income	$ (896)	$ 19,697
Basic weighted average common shares outstanding (in shares)	15,636,387	14,247,019
Dilutive effect of stock options (in shares)	0	793,992
Diluted weighted average common shares outstanding (in shares)	15,636,387	15,041,011
Basic net income (loss) per share (in usd per share)	$ (0.06)	$ 1.38
Diluted net income (loss) per share (in usd per share)	$ (0.06)	$ 1.31

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands	Jan. 12, 2016	Oct. 13, 2015	Mar. 31, 2016	Mar. 31, 2015
Business Acquisition [Line Items]
Payments to acquire business			$ 4,850	$ 0
Product sales			14,122	3,056
Net (loss) income			(896)	$ 19,697
Non-Alcohol Docetaxel Injection | Docetaxel product rights
Business Acquisition [Line Items]
Payments to acquire business	$ 4,850	$ 250
Fair value of contingent consideration liability	6,370		6,529
Intangible assets acquired	$ 11,220
Royalties on Gross Profits | Non-Alcohol Docetaxel Injection | Docetaxel product rights
Business Acquisition [Line Items]
Contingent consideration, percentage of gross profits	25.00%
Non-Alcohol Docetaxel Injection
Business Acquisition [Line Items]
Product sales			868
Net (loss) income			$ (867)

Acquisitions - Change in Fair V

Acquisitions - Change in Fair Value of Contingent Consideration Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in fair value		$ 159	$ 0
Non-Alcohol Docetaxel Injection | Docetaxel product rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Opening Balance January 12, 2016	$ 6,370
Changes in fair value	159
Closing Balance March 31, 2016	$ 6,529	$ 6,529

Acquisitions - Balance Sheet Cl

Acquisitions - Balance Sheet Classification of Contingent Consideration Liability (Details) - Non-Alcohol Docetaxel Injection - Docetaxel product rights - USD ($) $ in Thousands	Mar. 31, 2016	Jan. 12, 2016
Business Acquisition [Line Items]
Total acquisition related contingent consideration	$ 6,529	$ 6,370
Accrued royalty payable
Business Acquisition [Line Items]
Total acquisition related contingent consideration	1,012	1,012
Long term royalty payable
Business Acquisition [Line Items]
Total acquisition related contingent consideration	$ 5,517	$ 5,358

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw material	$ 5,208	$ 8,687
Work in process	0	6,044
Finished products	2,553	311
Inventories	$ 7,761	$ 15,042

Balance Sheet Accounts - Prepai

Balance Sheet Accounts - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Prepaid product costs	$ 134	$ 85
Prepaid FDA user fee	373	551
Prepaid insurance	651	218
Prepaid research and development	194	283
Prepaid income taxes	489	508
All other	207	220
Total Prepaid expenses and other current assets	$ 2,048	$ 1,865

Balance Sheet Accounts - Accrue

Balance Sheet Accounts - Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Components of Accrued Expenses [Line Items]
Accrued research & development	$ 1,258	$ 1,784
Accrued professional fees	817	792
Accrued salary and other compensation	1,149	2,242
Accrued product costs	5,918	9,232
Accrued other	428	0
Deferred rent	538	521
Total Accrued expenses	19,561	24,405
The Medicines Company
Components of Accrued Expenses [Line Items]
Royalties due	7,166	6,948
SciDose
Components of Accrued Expenses [Line Items]
Royalties due	1,474	1,637
Sandoz, Inc.
Components of Accrued Expenses [Line Items]
Royalties due	$ 813	$ 1,249

Balance Sheet Accounts - Deferr

Balance Sheet Accounts - Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 0	$ 6,000
Asset sales
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	6,000
Asset sales excluding Tech Transfers | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	5,500
Tech Transfer | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 0	$ 500

Intangible Asset - Schedule of

Intangible Asset - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Useful Life (In Years)	18 years
Gross Carrying Amount	$ 11,220	$ 0
Accumulated Amortization	(104)	0
Net Book Value	11,116	0
Amortization of intangible assets	$ 104	0
Docetaxel product rights
Finite-Lived Intangible Assets [Line Items]
Useful Life (In Years)	18 years
Gross Carrying Amount	$ 11,220	0
Accumulated Amortization	(104)	0
Net Book Value	$ 11,116	$ 0

Intangible Asset - Schedule o40

Intangible Asset - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2016 (remainder)	$ 468
2,017	623
2,018	623
2,019	623
2,020	623
All other	8,156
Net Book Value	$ 11,116	$ 0

Common Stock and Stock-Based 41

Common Stock and Stock-Based Compensation - Narrative (Details) - shares	Aug. 04, 2015	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		4 years
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized for grant (in shares)	500,000
Number of shares available for grant (in shares)		2,035,598

Common Stock and Stock-Based 42

Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 2,869	$ 384
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2,162	200
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 707	$ 184

Commitments - Narrative (Detail

Commitments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 21,345
Operating leases rent expense	162	$ 68
Future operating lease payments	$ 2,396

Commitments - Schedule of Opera

Commitments - Schedule of Operating Lease Obligations and Purchase Obligations (Details) $ in Thousands	Mar. 31, 2016USD ($)
Operating lease obligations
Total	$ 2,396
2,016	423
2,017	564
2,018	564
2,019	564
2,020	281
Beyond	0
Purchase obligations
Total	21,345
2,016	$ 21,345

Legal Proceedings (Details)

Legal Proceedings (Details) - patent	Oct. 21, 2013	Feb. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Patents allegedly infringed, number	1	2

Asset Sales (Details)

Asset Sales (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2011
Deferred Revenue Arrangement [Line Items]
Divestiture of businesses proceeds				$ 6,500
Other revenue		$ 6,000	$ 30,000
Proceeds from sale of diclofenac/misoprostol		1,750	$ 0
Asset sales
Deferred Revenue Arrangement [Line Items]
Deferred revenue, noncurrent				6,000
Other revenue	$ 6,000
Asset sales excluding Tech Transfers
Deferred Revenue Arrangement [Line Items]
Deferred revenue, noncurrent				5,500
Initiation of Tech Transfer
Deferred Revenue Arrangement [Line Items]
Divestiture of businesses proceeds				500
Deferred revenue, noncurrent				250
Completion of Tech Transfer
Deferred Revenue Arrangement [Line Items]
Divestiture of businesses proceeds				500
Deferred revenue, noncurrent				$ 250
Diclofenac-misoprostol
Deferred Revenue Arrangement [Line Items]
Proceeds from sale of diclofenac/misoprostol		$ 1,750
Royalty revenue, percentage of gross profits		25.00%
Royalty revenue term		5 years